CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

The model was initially launched by the Biden administration in February 2023, and CMS announced that SCD would be the first focus of the model the following January. This is the ...

CMS has reached agreements with drug manufacturers to provide gene therapies to treat sickle cell disease to Medicaid recipients under a new outcomes-based model. A total of 33 states, including the ...

Gabriella Ngang, of Farmington Hills, is one of three in Michigan to take part in a clinical trial of a new sickle cell ...

The Centers for Medicare and Medicaid Services has named 33 states, as well as Washington, D.C., and Puerto Rico, as participants in its Cell and Gene Therapy Access Model, which is designed to treat ...

So far in 2025, the Trump administration has cut more than $1 billion in NIH grants. That includes a study on sickle cell ...

The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene ...

Columnist Oluwatosin Adesoye, a doctor, sorts through the difference between sickle cell anemia and sickle cell disease — and more.

The Executive Director of the Ghana Foundation for Sickle Gene Action, Victoria Awo Twumasi, has appealed to President John Dramani Mahama to include full coverage of sickle cell disease (SCD) treatme ...

The US regulator has launched a new national initiative to help Medicaid programs fund gene therapies for sickle cell disease ...

Sickle cell disease is one of the most common genetic blood disorders in the world. It affects millions globally, with the ...